Citations

Showing 10 of 108119 citations.

Vascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, Melanie D. , Montagne, Axel , Nation, Daniel A. , Schneider, Lon S. , Chui, Helena C., Harrington, Michael G. , Pa, Judy , Law, Meng , Wang, Danny J.J. , Jacobs, Russell E. , Doubal, Fergus , Ramirez, Joel , Dichgans, Martin , Love, Seth , Bath, Philip M. , Markus, Hugh S. , Salman, Rustam Al‐Shahi , Kalaria, Rajesh N., Werring, David J. , Moskowitz, Michael A., Katušić, Zvonimir S. , Lazarov, Orly , Rehman, Jalees , Wellington, Cheryl L. , González, Héctor M. , Yuan, Chun , Lockhart, Samuel N. , Hughes, Timothy M. , Chen, Christopher , Sachdev, Perminder S. , O’Brien, John T. , Pantoni, Leonardo , Gustafson, Deborah , Biessels, Geert Jan , Wallin, Anders , Wong, Adrian , Passmore, Peter , Barkof, Frederick, Muller, Majon , Román, Gustavo C. , Hamel, Édith , Seshadri, Sudha , Buchem, Mark A. van , Arvanitakis, Zoe , Drewes, Lester R. , Hachinski, Vladimir , Wardlaw, Joanna M. , Kalaria, Raj N. , Dichgans, Martin , O'Brien, John Tiernan , Wardlaw, Joanna Marguerite , Seshadri, Sudha , Sachdev, Perminder S , Sagare, Abhay P. , Chui, Helena C. , Black, Sandra E. , Nedergaard, Maiken , Benveniste, Helene , Iadecola, Costantino , Allan, Stuart McRae , Quinn, Terence J , Carare, Roxana Octavia , Touyz, Rhian M. , Williams, Steven , Lutz, Sarah E. , Minshall, Richard D. , Davis, Thomas P. , Gonzalez, Hector M , Skoog, Ingmar , Biessels, Geert Jan , Smith, Eric Edward , Mok, Vincent , Breteler, Monique M.B. , Gottesman, Rebecca F. , Schneider, Julie A. , Finch, Caleb E. , Toga, Arthur W. , Zloković, Berislav V. , Al-Shahi Salman, Rustam , Werring, David John , Wang, Danny J J

Mayo Clinic

Alzheimer's & Dementia | January 11, 2019 | Volume: 15 | Issue: 1 | Pages: 158-167

10.1016/j.jalz.2018.07.222 | PMID 30642436 Get It

Abstract Increasing evidence recognizes Alzheimer's disease (AD) as a multifactorial and heterogeneous disease with multiple contributors to its pathophysiology, including vascular dysfunction. The recently updated AD Research Framework put forth by the National Institute on Aging–Alzheimer's Association describes a biomarker‐based pathologic definition of AD focused on amyloid, tau, and neuronal injury. In response to this article, here we first discussed evidence that vascular dysfunction is an important early event in AD pathophysiology. Next, we examined various imaging sequences that could be easily implemented to evaluate different types of vascular dysfunction associated with, and/or contributing to, AD pathophysiology, including changes in blood‐brain barrier integrity and cerebral blood flow. Vascular imaging biomarkers of small vessel disease of the brain, which is responsible for >50% of dementia worldwide, including AD, are already established, well characterized, and easy to recognize. We suggest that these vascular biomarkers should be incorporated into the AD Research Framework to gain a better understanding of AD pathophysiology and aid in treatment efforts.
The Needle-and-Knife Technique: A Safe Technique for Anterolateral Portal Placement in Elbow Arthroscopy
Thaveepunsan, Sutee , Shields, Maegan N. , O’Driscoll, Shawn W. , Fitzsimmons, James S

Mayo Clinic

Orthopaedic Journal of Sports Medicine | January 11, 2019 | Volume: 7 | Issue: 1 | Pages: No page available

10.1177/2325967118817232 | PMID 30729140 Get It

Background: Safe and effective portal placement is crucial for successful elbow arthroscopy. Various techniques for anterolateral portal placement in elbow arthroscopy have been described, yet radial nerve injuries are commonly reported. Purpose: To report on the technique and safety of anterolateral portal placement by the needle-and-knife method and its clinical applications. Study Design: Case series; Level of evidence, 4. Methods: A retrospective review was completed of patients who underwent an arthroscopic procedure in the anterior compartment of the elbow and anterolateral portal placement. Patients were evaluated immediately postoperatively and at subsequent visits and were monitored for signs of radial nerve injury. Results: A total of 460 patients met the inclusion criteria, of which 309 (67%) underwent the needle-and-knife technique. There was 1 case (0.3%) of temporary radial nerve palsy. For the remaining 151 patients who underwent anterolateral portal placement by other techniques, there were 2 cases of temporary radial nerve palsy (1.3%). There were no cases of the needle-and-knife technique being unsuccessful or abandoned in lieu of a different technique. Use of the needle-and-knife technique increased over time with experience and practice. Initially, contraindications to this technique included impaired view of the lateral side of the anterior compartment of the elbow caused by severe intra-articular scar (65%), extensive synovitis (10%), or large osteophytes or loose bodies (10%). For the remaining patients (15%) who did not have portals placed via the needle-and-knife technique, alternate techniques were used for teaching purposes. Conclusion: The needle-and-knife technique is reproducible and easy to perform by a clinician instructed in its use and trained in elbow arthroscopy. Its main advantage is that it permits the surgeon to safely slide the knife along the lateral supracondylar ridge, releasing the scarred capsule and thereby increasing the available space in which to work. Enlarging the working space inside scarred and contracted elbows cannot be accomplished by distending the capsule.
Percutaneous Embolization of an Inferior Mesenteric Artery Aneurysm in a Patient With Type IV Ehlers-Danlos Syndrome
Rahman, Qasim , Naidu, Sailen G., Chong, Brian W. , Stone, William M., Naidu, Sailendra

Mayo Clinic

Vascular and Endovascular Surgery | January 11, 2019 | Volume: 53 | Issue: 4 | Pages: 343-347

10.1177/1538574418824185 | PMID 30630391 Get It

Ehlers-Danlos syndrome (EDS) refers to a group of genetic disorders involving the connective tissues. Type IV EDS impairs type III collagen that is responsible for vessel integrity. Patients with type IV EDS are susceptible to vascular and visceral complications, including aortic aneurysms, pseudoaneurysms, dissections, and spontaneous rupture of internal organs. Treating aneurysms with open surgery versus endovascular techniques each carry a unique risk-to-benefit ratio that must be applied to each individual carefully. We present a patient with type IV EDS who presented with a rapidly growing inferior mesenteric artery aneurysm. The patient was treated with a percutaneous endovascular technique using coils and n-butyl-cyanoacrylate glue.
The intraoperative accuracy of maxillary balloon dilation: a blinded trial
Jensen, Brett T., Holbrook, Eric H. , Chen, Philip G. , Luong, Amber , Marino, Michael J. , Yao, William C. , Holbrook, Eric H , Chen, Philip G , Yao, William C

Mayo Clinic

International Forum of Allergy & Rhinology | January 10, 2019 | Volume: 9 | Issue: 5 | Pages: 452-457

10.1002/alr.22286 | PMID 30629822 Get It

BackgroundBalloon sinus dilation (BSD) is a commonly performed sinus procedure in the United States. Several cadaveric studies have evaluated BSD accuracy and the maxillary sinus has consistently been shown to be the most challenging to cannulate. We designed an independent study to evaluate the intraoperative accuracy of maxillary sinus BSD.MethodsA prospective, single‐blinded trial evaluating the accuracy of maxillary sinus BSD was performed using 2 commercially available BSD systems (guidewire‐ and probe‐based systems) randomly assigned to patients undergoing endoscopic surgery for chronic rhinosinusitus without nasal polyps (CRSsNP) or a skullbase approach in patients without sinus disease. All patients underwent maxillary BSD followed by uncinectomy to reveal dilation of the natural maxillary sinus ostia. The recorded procedures were reviewed by 3 fellowship‐trained rhinologists from different institutions blinded to the BSD system utilized. The primary endpoint compared accuracy of maxillary BSD attempts. The secondary endpoint compared accuracy between the 2 systems.ResultsTwenty‐nine maxillary BSD procedures were performed in 18 patients (age range, 20‐79 years; mean, 51 years) without nasal polyposis undergoing maxillary antrostomy as part of a more extensive procedure. BSD was successful in 18 of 29 (62%) attempts and unsuccessful in 9 of 29 (31%) attempts, with statistically “almost perfect” interrater agreement (kappa = 0.86). There was no statistical difference between the 2 BSD systems (p = 0.81).ConclusionMaxillary BSD appeared to be less accurate in living patients when compared with findings from previously published cadaver studies. There were no differences in accuracy between the probe‐ and guidewire‐based systems. This is the first non‒industry‐sponsored study evaluating maxillary sinus BSD in living patients. Further studies are needed to investigate the clinical implications of our findings.
Atypical Fundus Mass in a Child
Li, Lucy , Dalvin, Lauren A. , Shields, Carol L.

Mayo Clinic

JAMA Ophthalmology | January 10, 2019 | Volume: 137 | Issue: 3 | Pages: 322

10.1001/jamaophthalmol.2018.5443 | PMID 30629102 Get It

Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey
Kim, Hyun‐seok , Yang, Ju Dong , El‐Serag, Hashem B. , Kanwal, Fasiha , Kim, H S , Yang, Ju Dong

Mayo Clinic

Journal of Viral Hepatitis | January 10, 2019 | Volume: 26 | Issue: 5 | Pages: 596-602

10.1111/jvh.13060 | PMID 30629790 Get It

Summary The World Health Organization has set the goal of reducing the hepatitis‐related mortality rate by 65% between 2015 and 2030. Diagnosis and awareness of infection is the first essential step towards achieving this goal. Our study examined the current awareness rate of chronic viral hepatitis in the United States and the potentially associated factors. In the National Health Nutrition and Examination Survey 2013‐2016, there were 11 488 persons who participated in serology testing for chronic viral hepatitis. We defined chronic hepatitis B virus (HBV) infection by HbsAg, HBV past exposure by anti‐HBc and hepatitis C virus (HCV) infection by HCV RNA. At risk for significant fibrosis was determined by AST to Platelet Ratio Index >0.7. Awareness of chronic HBV infection, past HBV exposure and HCV infection were present in 33.9%, 11.7% and 55.6% of participants, respectively. Among HCV‐infected baby boomers, the awareness was in 61.5%. The awareness of HBV infection was significantly higher in individuals with high education level. Age group (40‐60 years), women, non‐Black race/ethnicity and those with high household income who were born in the United States with insurance plans tend to be aware of their infection. For HCV, awareness was the lowest in Hispanics and Asians, foreign‐born who lived below the federal poverty level and low education level. Awareness among chronic viral hepatitis patients at risk for significant fibrosis was 62.0% in HBV and 38.2% in HCV infection. In conclusion, current awareness of chronic viral hepatitis in the United States remains suboptimal. Active public health policy to identify persons at risk and provide appropriate management is warranted.
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis
Al‐Mansour, Zeina , Li, Hongli , Cook, James R. , Couban, Stephen, Stewart, Douglas A. , Shea, Thomas C., Smith, Sonali M. , Marcellus, Deborah, Barton, Kevin, Mills, Glenn, Forman, Stephen J. , Leonard, John P. , Fisher, Richard I., Friedberg, Jonathan W. , Stiff, Patrick J. , Constine, Louis S , Porcu, Pierluigi , Winter, Jane N. , Kahl, Brad S. , LeBlanc, Michael , Rimsza, Lisa M.

Mayo Clinic

Leukemia & Lymphoma | January 10, 2019 | Volume: 60 | Issue: 8 | Pages: 1934-1941

10.1080/10428194.2018.1563691 | PMID 30628511 Get It

Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?
Jain, Tania , Khetarpal, Banveet Kaur , McCallen, Margaret, Betcher, Jeffrey, Ofori, Henry , Khera, Nandita , Slack, James L., Leis, José F., Sproat, Lisa Z., Noël, Pierre, Palmer, Jeanne , Kunze, Katie L. , Khetarpal, Banveet K, McCallen, Margaret R, Betcher, Jeffrey A, Ofori, Henry T, Jain, Tania

Mayo Clinic

Leukemia & Lymphoma | January 10, 2019 | Volume: 60 | Issue: 8 | Pages: 2034-2041

10.1080/10428194.2018.1562183 | PMID 30626239 Get It

The willingness of patients with gastroparesis to take risks with medications
Navas, Christopher M. , Lacy, Brian E. , Lacy, Brian E , Crowell, Michael D.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | January 10, 2019 | Volume: 49 | Issue: 4 | Pages: 429-436

10.1111/apt.15112 | PMID 30628106 Get It

SummaryBackgroundGastroparesis has a significant negative impact on patients’ quality of life. Only one medication is approved for gastroparesis and it is associated with a significant risk of side effects.AimTo assess the willingness of patients to take risks associated with medications to treat gastroparesis symptoms.MethodsWe developed a questionnaire to assess medication risk‐taking behaviour in patients identified as having documented gastroparesis (consistent symptoms, normal upper endoscopy, delayed gastric emptying). The survey assessed demographics, symptoms, medication use, anxiety, depression and impulsivity. A standard reference gamble evaluated respondents’ willingness to take medication risks.ResultsTwo hundred seven questionnaires were mailed to patients, 103 questionnaires were completed. Seventy‐six percent were female; the mean age was 48 years; average duration of gastroparesis symptoms was 10 years. Self‐reported symptom severity was severe in 52% and moderate in 32%. Gastroparesis patients reported that they would accept a median 13.4% risk of sudden death to cure their symptoms using a hypothetical medication. Self‐reported gastroparesis symptom severity and Gastroparesis Cardinal Symptom Index scores correlated significantly with increased willingness to take risks associated with medications to treat gastroparesis, while anxiety was negatively associated.ConclusionsGastroparesis patients are willing to accept markedly high risks with a hypothetical medication to cure their symptoms. Patients with severe gastroparesis symptoms and higher Gastroparesis Cardinal Symptom Index scores were more willing to take these risks. This study, the first to quantify gastroparesis patients’ willingness to accept medication associated risks, should help clinicians through the complex maze of gastroparesis therapies and their associated risks and benefits.